Takeda ready to sell therapy to facilitate green light to acquire Shire by competition watchdogs

Takeda Pharmaceutical has informed the European Commission that it is willing to divest the investigational Chron’s disease therapy for  treatment named SHP647, now owned by Shire. The announcement aims to facilitate an approval by the EU antitrust regulators to the $62bn acquisition of the Ireland-based group, announced last May. SHP647 is a highly-promising therapy in Shire’s portfolio and it is currently in the latest testing stages with a Phase III clinical trial still underway.

Source: Takeda